Setting Standards of Care in Prenatal Screening

Prenatal screening delivers accurate answers for sensitive decisions

Assessing the health of an unborn baby is a sensitive matter that demands precise tests and accurate risk calculation. The B·R·A·H·M·S KRYPTOR compact PLUS meets the strict quality standards of the Fetal Medicine Foundation.


Meeting the needs of to-be parents

The B·R·A·H·M·S KRYPTOR analyzer platforms have maintained certification from the Fetal Medicine Foundation since 1999 through a continuous commitment to highest quality assurance. Furthermore, performance of the B·R·A·H·M·S KRYPTOR analyzer platform is OSCAR (One-Stop Clinic for Assessment of Risk) compatible, where the risk of Down syndrome is determined before 14 weeks of gestation, screening is safe and has a detection rate of 90%, and results can be generated in about one hour.


Precise, fast and reliable

Highly accurate, non-invasive biomarker testing is an important tool in prenatal screening of Down syndrome and preeclampsia. Given the sensitivity of the information, results must be fast, precise and reliable. The B·R·A·H·M·S KRYPTOR analyzer platform affords market-leading precision and stability in detecting prenatal screening biomarkers, a distinction that is backed by 16 years of continuous internal quality assessments and independently confirmed by the external quality assessment service UKNEQAS since 2003. The Fetal Medicine Foundation has approved all prenatal screening biomarkers on the B·R·A·H·M·S KRYPTOR analyzer platform, making it the instrument of choice for first and second trimester prenatal screening.


About the FMF

The Fetal Medicine Foundation aims to improve the health of pregnant women and their babies through research and training in fetal medicine. The Foundation has introduced educational programs for healthcare professionals and parents, as well as certificates of competence in different aspects of fetal medicine (Learn more).

B·R·A·H·M·S KRYPTOR GOLD and B·R·A·H·M·S KRYPTOR prenatal screening assays are fulfilling the requirements established by Fetal Medicine Foundation (FMF) for the biochemical screening for chromosomal abnormalities and pre-eclampsia.
Download Fetal Medicine Foundation Certificate >


Independent Quality Assessment

The UK NEQAS is an independent quality assessment service that facilitates optimal patient care by providing comprehensive evaluation of laboratory medicine services. UK NEQAS helps ensure that the results of investigations are reliable and comparable wherever they are produced.

Further links on prenatal screening

thermo scientific applied biosystems invitrogen fisher scientific unity lab service